General Information
- The Lung in Scleroderma
- Course Director: Virginia D. Steen, MD, NSF Medical Scientific Advisory Board, Professor Division of Rheumatology, Georgetown University
- Release Date: 10/25/2024
- Expiration Date: 10/25/2025
Jointly provided by Postgraduate Institute for Medicine and National Scleroderma Foundation
Target Audience
This activity is intended for physicians & registered nurses engaged in the care of patients with systemic scleroderma.
Educational Objectives
After completing this activity, the participant should be better able to:
- Develop materials to increase awareness about the need for early diagnosis and treatment of pulmonary hypertension and interstitial fibrosis in systemic sclerosis.
- Implement recent updates on the diagnostic methods and outcome measures used in scleroderma patients with pulmonary hypertension or interstitial fibrosis.
- Implement evidence-based treatments to improve the quality of care delivered to patients with SSc-ILD.
Faculty
Virginia D. Steen M.D.
NSF Medical Scientific Advisory Board
Georgetown University
Laura Hummers M.D.
NSF Medical Scientific Advisory Board
Clinical Director, Division of Rheumatology, Johns Hopkins Medicine
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:
Virginia D. Steen M.D.
Consulting fees from: Boehringer Ingelheim, CSL Behring, Eicos
Grant funding from: Boehringer Ingelheim, Kadman, Accelleron, Genetec, Biogen, Eicos, Roche, Prometheus
Laura Hummers M.D.
Consulting fees from: Boehringer Ingelheim, Ortho Dermatologic, Biotest, CSL Behring
Grant funding from: Cumberland Pharmaceuticals, Boehringer Ingelheim, Prometheus, Kadmon, Eicos, Glaxo Smith Kline, Mitsubishi Tanabe, Horizon, Asta Zeneca
The PIM planners and others have nothing to disclose. The National Scleroderma Foundation planners and others have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and National Scleroderma Foundation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2 contact hours. (If applicable, for APRNs, enduring activity) Designated for 2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Fee Information
There is no fee for this educational activity.
Instructions for Obtaining Credit
During the period of accreditation, participants must 1) read the learning objectives and disclosures; 2) study the educational content; and 3) complete the post-test (if applicable) and the evaluation form. To answer the questions, click on your selected choice for each answer and then proceed to the next question. If applicable, your post-test will automatically be graded. After successfully completing these items, your certificate will be made available immediately. Click on View Certificate, and print or download the certificate for your records.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.